US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

September 19, 2023

Eli Lilly And Company v. Revive RX, LLC

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. August 05, 2026

    Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs

    A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair-competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight-loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive's argument that compounded drugs fall outside state "new drug" laws.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login